News
New antibody cuts the fat in NAFLD
BOSTON – In a phase 1b trial, treatment with tolerable doses of the bispecific antibody reduced hepatic fat fraction by a mean of 38%.
News
DUR-928 shows promise for alcoholic hepatitis
BOSTON – Among 15 patients with severe alcoholic hepatitis, 87% responded to treatment (Lille score less than 0.45).
News
Glecaprevir/pibrentasvir highly effective in HCV genotype 3, among others
BOSTON – Pangenotypic regimen may further progress toward elimination of hepatitis C, investigators say.
News
Hepatitis C vaccine alters viral trajectory, but fails in chronic infection protection
BOSTON – First-ever randomized study does suggest changes in peak HCV RNA and an HCV RNA change after infection.
News
Fenofibrate fights increased triglycerides in NASH
BOSTON – Patients with advanced fibrosis caused by NASH had limited increase in triglycerides after treatment with varying doses of fenofibrate....
News
High doses of FXR agonist tropifexor reduce hepatic fat, serum ALT in patients with NASH
BOSTON – Mild pruritus, minor decreases in LDL cholesterol are notable adverse effects of treatment, similar to others in class.
News
Duodenal mucosal resurfacing has metabolic effects in type 2 diabetes
BOSTON – Improvements in HbA1c and NASH biomarker favored the procedure over sham procedure in first-ever randomized, double-blind...
News
Terlipressin reversed hepatorenal syndrome in large prospective study
BOSTON – Durable response linked to less need for early renal replacement therapy, investigators say
Article
Heart Failure in Older Adults: A Geriatrician Call for Action
As the population ages, heart failure is becoming a major public health challenge; clinicians need further evidence-based treatments to bridge the...
News
Bariatric surgery shows metabolic benefits in lower-BMI patients
LAS VEGAS – Data from 45,000 patients showed that those who had a BMI below 35 kg/m2 benefited as much as those with higher BMIs.